BioBridgeX
Log inCompare quotes
Modality

Oligonucleotide (ASO / siRNA) CRO and CDMO vendors

Free for buyersNeutral marketplace
Quick answer

Outsourcing an oligonucleotide (ASO or siRNA) program means sourcing solid-phase synthesis, sequence and chemistry optimization, conjugation (GalNAc), LNP or delivery formulation, and a heavy analytical load: mass spec, anion-exchange and ion-pair HPLC, and impurity profiling. Specialist CRO and CDMO partners handle GMP oligo manufacturing and stability. On BioBridgeX you compare qualified suppliers free, as the neutral marketplace, and contract directly with the supplier you choose.

Oligonucleotide (ASO / siRNA) CRO and CDMO vendors on BioBridgeX

We are qualifying and publishing Oligonucleotide (ASO / siRNA) CRO and CDMO vendors now. Tell us what you need and we will match you with vetted vendors, or list your organization to be among the first.

What does it take to develop and manufacture a Oligonucleotide (ASO / siRNA) drug?

Oligonucleotides look deceptively simple on paper, a short string of nucleotides, but the chemistry that makes them work as drugs is where the difficulty lives. An antisense oligo (ASO) and a small interfering RNA (siRNA) are made the same way at the bench, by solid-phase phosphoramidite synthesis, yet almost everything else differs: ASOs are single strands that recruit RNase H or block splicing, siRNAs are duplexes that load into RISC. Both depend on backbone and sugar modifications (phosphorothioate linkages, 2'-MOE, 2'-O-methyl, 2'-fluoro, LNA, and the morpholino variant) to survive nucleases and stay in the body long enough to act. Get the modification pattern wrong and you have a sequence that is potent in a dish and useless in an animal.

On the discovery and preclinical side, the work that gets outsourced is sequence design and screening, chemical modification scans, in vitro potency and knockdown assays, off-target and hybridization-dependent toxicity screening, and the delivery decision. Delivery is the whole game for this modality. GalNAc conjugation gets siRNA and some ASOs into hepatocytes cleanly, which is why so many approved oligos are liver-targeted; everything outside the liver (CNS via intrathecal dosing, muscle, tumor) is harder and often leans on lipid nanoparticles or newer conjugates. A CRO that understands which delivery approach fits your target tissue saves you a year of dead ends.

On the CMC and manufacturing side, this is where specialist oligo CDMOs separate themselves from generalists. Solid-phase oligo synthesis at scale is its own discipline: it needs the right synthesizer column chemistry, controlled-pore-glass or polystyrene supports, amidite supply and quality, and a real handle on process-related impurities (n-1 and n+1 shortmers, depurination products, P=O versus P=S diastereomers). The analytical burden is heavier than most small molecules: identity and purity by ion-pair reversed-phase LC-MS, anion-exchange HPLC, capillary gel electrophoresis, and impurity characterization down the chain. A generalist API shop can run an HPLC, but it usually does not have validated oligo-specific methods, the purification trains (large-scale ion-exchange and reversed-phase), or the regulatory history of filing oligo CMC sections. For GalNAc or LNP work you also need conjugation and formulation capability under GMP, which narrows the field further.

How do you choose a CRO or CDMO for Oligonucleotide (ASO / siRNA)?

The fastest way to waste budget on this modality is to hire a competent generalist who has never actually shipped an oligo. Use a checklist built around the things that are specific to ASO and siRNA work, and ask for evidence on each, not assurances.

  • Relevant platform and track record: confirmed solid-phase synthesis experience with your chemistry (phosphorothioate, 2'-MOE/2'-OMe/2'-F, LNA, or morpholino), and named programs they have actually delivered, ideally with at least one that reached the clinic. Ask which modality they do most, ASO single strands or siRNA duplexes, because annealing and duplex QC are a separate skill.
  • Delivery and conjugation fit: real GalNAc conjugation capability if you are targeting liver, or LNP / lipid-conjugate formulation if you are going elsewhere. Match this to your target tissue before anything else.
  • GxP and analytical capability for this modality: validated oligo-specific methods (ion-pair LC-MS, anion-exchange HPLC, CGE), impurity profiling for shortmers and process-related species, and GMP status appropriate to your stage (non-GLP for discovery screens, GLP for the tox package, GMP for clinical supply).
  • Capacity and scale: can they take you from milligram research batches through GLP tox material to GMP clinical (and eventually commercial) supply without a disruptive tech transfer? Oligo demand can jump fast once a program reads out; confirm purification train size and suite availability.
  • Regulatory experience: have they written oligonucleotide CMC sections that survived FDA or EMA review? Oligo impurity specs and the genotoxicity questions around them are an area where regulator-tested experience genuinely de-risks your filing.
  • IP, supply chain, and quality: clear ownership of sequences and process know-how, transparent amidite and starting-material sourcing (single-source amidite risk is real), and a quality system with audit history you can review. Confirm stability-program capability, since oligo stability data drives shelf life.

Frequently asked questions

What is the difference between an ASO and an siRNA, and does it change who I should hire?
Yes, it changes the supplier profile. Both are made by solid-phase phosphoramidite synthesis, so a synthesis CRO can usually make either. The difference is downstream. An ASO is a single strand that works through RNase H cleavage or splice modulation, while an siRNA is a duplex of two annealed strands that loads into RISC, which means siRNA work adds an annealing step, duplex purity and stoichiometry QC, and often a sense-strand conjugate. If you are running siRNA, confirm the supplier routinely handles duplex annealing and duplex-specific analytics, not just single-strand synthesis. The modification chemistry and delivery strategy also tend to differ between the two.
Why do oligonucleotide programs need GalNAc conjugation or LNP formulation, and can the same supplier do both synthesis and delivery?
Naked oligos distribute poorly and rarely reach the cells you want. GalNAc conjugation binds the asialoglycoprotein receptor on hepatocytes and delivers siRNA and some ASOs to the liver efficiently, which is why most approved oligos are liver-targeted. For tissues outside the liver you typically need lipid nanoparticles or newer conjugates, plus, for CNS, intrathecal delivery. Some specialist oligo CDMOs do synthesis, conjugation, and GMP formulation under one roof; many do not. If your delivery approach is fixed, make it a gating question early, because a synthesis-only shop will hand off the hardest part to a third party.
What analytical methods should an oligonucleotide CDMO have validated?
At minimum: identity and purity by ion-pair reversed-phase LC-MS, anion-exchange HPLC for charge-related impurities, and capillary gel electrophoresis. They should profile process-related impurities specific to oligos, the n-1 and n+1 shortmers, depurination and longmer species, and (for siRNA) duplex purity and single-strand content. Generalist API CDMOs often lack validated oligo-specific methods and the purification trains that go with them. Ask to see method validation packages and an example certificate of analysis for an oligo, not for a small molecule.
How does manufacturing scale work for oligos, and when does scale become a bottleneck?
Solid-phase synthesis scales by column and synthesizer size, and large-scale ion-exchange and reversed-phase purification trains. Research and early tox material is straightforward; the squeeze usually comes at the GMP clinical stage and again if a program needs commercial tonnage, because amidite supply and purification suite capacity can constrain throughput. The practical move is to pick a partner who can carry you from milligram batches through GMP clinical supply without a disruptive tech transfer mid-program, and to confirm their suite availability and amidite sourcing before you commit, since a single-source amidite is a real supply risk.
Do early oligonucleotide screening studies need to be GLP?
Usually not. Sequence screening, modification scans, in vitro potency and knockdown assays, and exploratory off-target work are research-grade and run under good scientific practice, not GLP. GLP applies to the definitive safety studies that support your IND, which sit in the IND-enabling stage, and GMP applies to material destined for human use. A common and avoidable mistake is paying GMP or GLP prices for exploratory discovery work. Clarify with each supplier whether a given study is exploratory or regulatory-grade before it starts, and scope accordingly.
How does sourcing oligonucleotide CRO and CDMO suppliers through BioBridgeX work?
You describe the program (ASO or siRNA, your chemistry, the delivery approach, target tissue, stage, and the services you need) and you are matched with qualified oligonucleotide CRO and CDMO suppliers who do that specific work. You compare them on relevant track record, analytical and GMP capability, and transparent quotes, then choose. The platform is free for buyers; suppliers pay a flat 2% fee. When a program needs more than one partner, say a synthesis CDMO plus a separate formulation group, you compare quotes and contract directly with each supplier in one place, with BioBridgeX as the neutral marketplace, across all indications and modalities.

Source Oligonucleotide (ASO / siRNA) work with one contract

Compare transparent quotes from qualified Oligonucleotide (ASO / siRNA) CRO and CDMO vendors, then contract once. Free for buyers.

Compare quotes